Moreover, combination of low-dose TSA with anti-PD-L1 in syngeneic mouse tumor models results in an M1-like phenotype with diminished the immunosuppressive function of TAMs and promotes the overall anti-tumor immune response, leading to significantly reduced mouse tumor burden and a significant prolongation in survival compared with that in the control mice. This evidence concerns the gene CD274 and neoplasm.